Hormone Replacement Therapy May Prevent Alzheimer's in Women

Hormone Replacement Therapy May Prevent Alzheimer's in Women
Hormone Replacement Therapy May Prevent Alzheimer's in Women - According to research, women who used HRT later in life had superior memory, cognition and larger brain volumes than women who did not use HRT. APOE4 is the gene with the highest risk of developing Alzheimer's disease. It is a public domain image.

A University of East Anglia study shows that women at risk for Alzheimer's disease may benefit from hormone replacement therapy (HRT). The study shows that among women with the APOE4 gene, the highest risk factor for Alzheimer's disease, use of HRT is associated with superior memory, cognition and greater brain volumes later in life.

The study team discovered that HRT is most successful when started during perimenopause, the first stage of the menopausal process.

The study was led by Professor Anne-Marie Minihane of the University of East Anglia Norwich Medical School and led by Professor Craig Ritchie of the University of Edinburgh.

Dr. Minihane said: “We know that 25% of women in the UK are carriers of the APOE4 gene and that women make up about two-thirds of Alzheimer's patients.

“In addition to living longer, the effects of menopause and the stronger APOE4 genetic risk factor in women are believed to be reasons for the higher female prevalence. We wanted to find out if HRT could protect APOE4 carriers from cognitive impairment.

The European Alzheimer's Prevention study was created to track participants' brain health over time, and the research team analyzed data from 1.178 women who participated in the initiative.

The experiment spanned 10 countries and tracked participants' brains from being "healthy" to being diagnosed with dementia in certain situations. If a participant was over 50 years old and without dementia, he was included in the study.

The research team examined their findings to determine how HRT affects women with the APOE4 genotype.

From the University of East Anglia Norwich School of Medicine, Dr. Rasha Saleh said: “We discovered that the use of HRT is associated with superior memory and larger brain sizes among at-risk APOE4 gene carriers. When HRT was started early – during the perimenopausal transition to menopause – the links were particularly clear.

Finding new treatments is extremely important, as only a few pharmacological alternatives have been available for Alzheimer's disease for the past 20 years. If the results of an intervention study had supported the effects of HRT in this observational study, the brain age would have been many years younger.

Dr. Anne Marie Minihane says, “In our study, we used MRI images to examine the relationships between brain volumes and cognition. Although we have not studied cases of dementia, cognitive function and smaller brain sizes are indicators of future dementia risk.

Professor at UEA Norwich Medical School. “It is too early to say definitively that HRT reduces the risk of dementia in women, but our results underscore the potential benefit of HRT and personalized therapy in reducing Alzheimer's risk,” said Michael Hornberger.

“The next phase of this study will involve conducting an intervention trial to confirm the impact of early initiation of HRT on cognition and brain health. Analysis of the most advantageous types of HRT will also be crucial,” he continued.

Professor at Edinburgh University Craig Ritchie said, “This important result from the EPAD Cohort highlights the need to question multiple assumptions regarding early Alzheimer's disease and its management, particularly when considering women's brain health.

“The effect on brain changes detected by both cognitive and MRI supports the idea that HRT has real advantages. However, these initial findings need to be replicated in other populations.

Initiation of HRT in APOE4-only carriers is associated with improved delayed memory and larger entorhinal and amygdala sizes. This may be a useful targeted approach to reduce the higher lifetime risk of AD in this sizable subset of populations at risk. To prove causality, results from a fit-for-purpose RCT with prospective recruitment based on the APOE genotype should be validated.

source: neurosciencenews




Günceleme: 16/01/2023 17:17

Similar Ads

Be the first to comment

your comment